EZH2 and prostate carcinoma: Prior to the present study, three molecular mechanisms were identified that could be responsible for overexpression of EZH2 in prostate cancer--amplification of the EZH2 gene [8], the deletion of its negative regulator miR-101 [5], and transcriptional regulation of EZH2 by ETS gene family members [12, 13].